| Sep 3 |
Following Up On Phathom Pharmaceuticals
|
| Aug 19 |
Phathom Pharmaceuticals prices $130M equity offering
|
| Aug 19 |
Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants
|
| Aug 10 |
Phathom Pharmaceuticals, Inc. (PHAT) Q2 2024 Earnings Call Transcript
|
| Aug 8 |
Phathom Pharmaceuticals Non-GAAP EPS of -$1.25, revenue of $7.3M
|
| Aug 8 |
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 8 |
Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
|
| Jul 30 |
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients
|
| Jul 29 |
Phathom Pharmaceuticals to Report Second Quarter 2024 Financial Results and Provide Business Update on Thursday, August 8, 2024
|
| Jul 18 |
Phathom Pharma announces Voquezna label expansion
|
